Resources
Stay informed with the latest news, research, and information about memory health and Alzheimer's care.
Clinical Update
New TGA-Approved Alzheimer's Therapies
The Therapeutic Goods Administration (TGA) has approved two new treatments for people with Mild Cognitive Impairment (MCI) or early Alzheimer's disease: Donanemab (brand name Kisunla) and Lecanemab (brand name Leqembi). These represent a significant advance in Alzheimer's care and are now available at The Memory Centre for eligible patients.
Patient eligibility criteria:
- Evidence of a "rapid forgetting" pattern of memory impairment
- Diagnosis of mild cognitive impairment or mild dementia due to Alzheimer's disease
- Minimal impairment in daily functioning
- MMSE score between 20 and 28
- Confirmed amyloid pathology on brain imaging
Useful Links
Alzheimer's Australia
National peak body providing support, education, and advocacy for people affected by dementia.
Visit Website
TGA – Therapeutic Goods Administration
Official information on approved medicines and medical devices in Australia.
Visit Website
My Aged Care
Australian Government portal for aged care services, assessments, and support.
Visit Website
Carer Gateway
Support and services for carers of people with dementia and other conditions.
Visit Website